Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6DKK2
UPID:
TTC19_HUMAN
Alternative names:
-
Alternative UPACC:
Q6DKK2; A8MZ52; B3KP62; B4DN65; Q2M248; Q7L3U8; Q9H6G3; Q9NXB2
Background:
Tetratricopeptide repeat protein 19, mitochondrial (TPR19), plays a crucial role in maintaining the structural and functional integrity of mitochondrial respiratory complex III. It facilitates the physiological turnover of the Rieske protein UQCRFS1, essential for cellular energy production. TPR19 is also involved in the clearance of UQCRFS1 N-terminal fragments, enhancing complex III's catalytic activity.
Therapeutic significance:
TPR19's involvement in Mitochondrial complex III deficiency, nuclear type 2, a disorder affecting multiple body systems, underscores its therapeutic potential. Targeting TPR19 pathways could lead to novel treatments for mitochondrial disorders, emphasizing the importance of understanding its biological mechanisms.